6 Allergy Headlines You Missed in October 2025

This November, breakthroughs in allergy research are capturing attention across prevention, oral immunotherapy, and chronic rhinosinusitis management. Real-world data show declining peanut allergy rates linked to early introduction guidelines, while low-dose peanut OIT offers effective desensitization with fewer reactions. Early formula feeding in newborns also emerged as a potential risk factor for food allergies.

On the treatment front, Oticara’s intranasal steroid cream and CM326, an anti-TSLP monoclonal antibody, demonstrated promising efficacy and safety in post-surgical CRS and CRSwNP, respectively. This month in review highlights the top 6 allergy news stories shaping October 2025.

Expert Perspective on HAE FDA News

FDA’s Approval of Donidalorsen for HAE, With William Lumry, MD

The US Food & Drug Administration (FDA) has approved donidalorsen (Dawnzera), the first RNA-targeted therapy for hereditary angioedema (HAE). Donidalorsen, an antisense oligonucleotide from Ionis Pharmaceuticals, reduces prekallikrein production, preventing bradykinin-mediated swelling. Phase 3 OASIS-HAE and OASISplus trials demonstrated up to 81% reduction in HAE attacks, with a durable response and improved quality of life over 3 years. Patients switching from other prophylactics, including lanadelumab and C1 esterase inhibitors, experienced further benefit.

HCPLive spoke with William Lumry, MD, founder of the Allergy & Asthma Specialists of Dallas, about the approval.

Real-World, Lasting Impact of 2015 Early Food Introduction Guidelines

Peanut Allergy Rates Plummet 10 Years After AAP Early Introduction Guidelines

A decade after the American Academy of Pediatrics (AAP) recommended early peanut introduction, new real-world data show peanut allergy rates in children have dropped sharply. Led by Stanislaw J. Gabryszewski, MD, PhD, at the Children’s Hospital of Philadelphia, the study found a 27% decline after the 2015 guidelines and a 43% decline after the 2017 addendum, with overall IgE-mediated food allergies also decreasing. Experts, including Ruchi Gupta, MD, MPH (Northwestern University Feinberg School of Medicine), and Vivian P. Hernandez-Trujillo, MD (Nicklaus Children’s Hospital), highlight ongoing challenges in implementation but view the findings as promising evidence that early allergen introduction can meaningfully reduce pediatric food allergy prevalence.

Related:

Peanut Allergy Decline Shows Success of Early Introduction Guidelines, With Stanislaw J. Gabryszewski, MD, PhD

Early Peanut Introduction Guidelines Linked to Drop in Food Allergy Rates

Promising Phase 2 Data

Intranasal Steroid Cream Post-Surgery Improves CRS Symptoms in Phase 2 Trial

Oticara’s intranasal steroid cream (betamethasone dipropionate) significantly improved symptoms in post-surgical chronic rhinosinusitis (CRS), according to phase 2 OT-007B trial results presented at AAO-HNSF 2025. The in-office, single-dose treatment led to meaningful reductions in the 4 Cardinal Symptom Score (4CSS) and SNOT-22, with durable improvements up to 9 weeks. Investigators, including Anders Cervin, MD, PhD, FRACS (University of Queensland), reported enhanced patient-reported outcomes, including sense of smell, and minimal systemic steroid exposure. The therapy was well-tolerated, with mostly mild adverse events.

1b/1a Study Findings on Chronic Rhinosinusitis

Anti-TSLP Monoclonal Antibody CM326 Shows Efficacy and Safety in CRSwNP

CM326, an anti-TSLP monoclonal antibody, demonstrated efficacy and safety in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 1b/2a study, co-led by Feng Lan, PhD, and Mu Xian, MD, from Beijing TongRen Hospital, Capital Medical University, showed significant reductions in nasal polyp scores, with patients having baseline plasma TSLP ≥330 fg/mL responding particularly well. CM326 also decreased eosinophil counts and plasma IL-5/IL-13 levels. The therapy was generally well-tolerated, with mostly mild or moderate adverse events and low immunogenicity.

Additional Significant Findings in Allergy

Low-Dose Peanut OIT (30 mg) Matches Benefits of 300 mg Dose With Fewer Reactions

A 30 mg maintenance dose of peanut oral immunotherapy (OIT) effectively increases reaction thresholds in children with peanut allergy, delivering clinical outcomes similar to the standard 300 mg dose. The study, led by Julia E.M. Upton, MD, MPH, at the Hospital for Sick Children, showed comparable immunological improvements with fewer systemic adverse events. This lower-dose approach may simplify OIT, improve safety, enhance tolerability, and reduce treatment discontinuation in pediatric patients.

Baby Formula in First 3 Days of Life May Increase Peanut Allergy Risk

New research suggests baby formula in the first 3 days of life may increase the risk of peanut and multiple food allergies. Study investigator Maheshwar Bhasin, PhD candidate from the University of Western Australia, found early formula feeding reduces colostrum intake, depriving infants of immune-boosting bioactive compounds. Exclusive colostrum feeding in the first 72 hours was linked to a lower allergy risk, highlighting its importance for infant immune and gut health and potential food allergy prevention strategies.